Follow The Filings

TLPH Talphera

Talphera earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by TLPH's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TLPH insider trades
  • $304K bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Vincent J. Angotti CEO
    Buy
    $125K 213,310 shares at $0.5900 +36% to stake
    Traded Mar 13 Filed Mar 25
  2. Shakil Aslam Chief Medical Officer
    Buy
    $28K 35,000 shares at $0.8100 +73% to stake
    Traded Feb 12 Filed Feb 20
  3. Vincent J. Angotti CEO
    Buy
    $86K 105,364 shares at $0.8100 +22% to stake
    Traded Feb 12 Filed Feb 20
  4. Raffi Asadorian CFO
    Buy
    $37K 45,000 shares at $0.8100 +97% to stake
    Traded Feb 12 Filed Feb 20

Also filed in the last 12 months, not counted as buying or selling: 13 stock grants and 11 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q FORM 10-Q
8-K 5.02,5.07,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q FORM 10-Q
SCHEDULE 13G/A —
DEF 14A FORM DEF 14A
DEFA14A FORM DEFA14A
424B7 FORM 424B7
8-K 2.02,9.01
10-K FORM 10-K
8-K 3.02
8-K 3.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
424B7 FORM 424B7
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q FORM 10-Q

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.